**Robust IPO pipelines and scheduled listings support continued activity through year-end 2026, even as higher Treasury yields introduce selectivity.** As of mid-October 2026, multiple offerings are priced or imminent, including Iambic Therapeutics and City Therapeutics on Nasdaq in mid-month, alongside international deals in Hong Kong and Japan. Year-to-date U.S. traditional IPO proceeds have already surpassed full-year 2025 levels (excluding outliers like SpaceX), fueled by AI infrastructure demand and broader sector participation. Goldman Sachs projects $175 billion in 2027 IPOs following a record 2026 issuance pace. However, the September Fed rate hike and 10-year yields near 5.3%—the highest since 2002—have compressed valuations and prompted postponements, such as OpenAI shifting to 2027. Traders monitor upcoming FOMC communications, Q4 economic data, and aftermarket performance of recent deals for signals on whether the window remains open for additional listings before year-end.